Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ADVENZYMES.NS
BuyFallen FavouriteAdvanced Enzyme Technologies Limited · Basic Materials · India · $350M · Avg Vol: $964K/d
COMPANY DESCRIPTION
Advanced Enzyme Technologies Limited, together with its subsidiaries, engages in the research, development, manufacture, and marketing of enzymes and probiotics in India, Europe, the United States, Asia, and internationally.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.4B | 6.2B | 6.4B | 7.4B | 11.3% | 7.5B | 8.5B | 10.0B | 15.6% |
| EPS (INR) | 9.45 | 11.92 | 11.72 | 15.08 | 16.9% | 14.84 | 16.34 | 19.40 | 13.4% |
| Shares | 111.8M | 111.8M | 111.9M | 111.9M | +0.1% | 110.9M | — | — | — |
| Debt | 335.0M | 473.1M | 393.5M | 320.1M | -1.5% | 321.2M | — | — | — |
| Equity | 12.4B | 13.2B | 14.2B | 16.3B | 9.7% | — | — | — | — |
| Op CF | 1.4B | 1.4B | 1.4B | 1.6B | 3.8% | 1.6B | — | — | — |
| Inv CF | -3.0B | -646.5M | -891.0M | -741.3M | — | — | — | — | — |
| Fin CF | -258.0M | -592.4M | -725.4M | -703.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Basic Materials, ranked by industry match, size, and score similarity. Cross-listings of ADVENZYMES.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ADVENZYMES.NS | Advanced Enzyme Technologies Limited(you) | $350M | 74 | Buy |
| JUBLCPL.NS | Jubilant Agri and Consumer Products Limited | $348M | 73 | Buy |
| NOCIL.NS | NOCIL Limited | $326M | 77 | Buy |
| YASHO.NS | Yasho Industries Limited | $513M | 71 | Buy |
| DDEVPLSTIK.NS | Ddev Plastiks Industries Limited | $294M | 81 | Strong Buy |
| INDIGOPNTS.NS | Indigo Paints Limited | $574M | 76 | Buy |
| TINNARUBR.NS | Tinna Rubber and Infrastructure Limited | $194M | 72 | Buy |
| SHREEPUSHK.NS | Shree Pushkar Chemicals & Fertilisers Limited | $174M | 74 | Buy |
| TATVA.NS | Tatva Chintan Pharma Chem Limited | $415M | 62 | Hold |
| POLYPLEX.NS | Polyplex Corporation Limited | $395M | 87 | Strong Buy |
Peer medians: ROE 10.1% · P/E 24.5x · Gross margin 38.4%